Light and sound therapy may fend off memory and cognitive damage for chemo patients
By
Aaron Dorman
Mar 08, 2024
A combination of light and sound therapy may be able to counteract the problems in the brain caused by chemo, new research shows.
AI may help predict mortality in dementia patients
Mar 05, 2024
The prediction was feasible across time frames using certain clinical features.
Timing of CSF biomarker divergence for Alzheimer’s disease, normal cognition varies
Feb 21, 2024
Estimated times of divergence of cerebrospinal fluid biomarkers vary from 18 years for Aβ42 to six years for cognitive decline.
American Stroke Association, Feb. 7-9
Feb 20, 2024
The conference featured presentations that emphasized basic, clinical and translational medicine and provided insight into the prevention, management and treatment of stroke.
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Bill calls for $165 million in funding for Alzheimer’s-related initiatives
By
Kimberly Bonvissuto
Feb 12, 2024
Bipartisan bills recently introduced in the US Senate and House of Representatives, if passed as written and signed into law, would fund public health initiatives related to Alzheimer’s disease to the...
Financial burden of dementia poses challenges for older adults, caregivers, payers: researchers
By
Kimberly Bonvissuto
Feb 09, 2024
The growing population of older adults brings with it an increased prevalence of Alzheimer’s disease and related dementias. Two new papers look at the increasing financial burden on people living with...
More news for Monday, Feb. 5
By
Kimberly Bonvissuto
Feb 05, 2024
Takeaways from NIC MAP’s fourth-quarter fundamentals release … Use of Medicaid wraparound services by dually eligible individuals varies by service, state … StartUp Health launches global Alzheimer’s...
Holistic dementia care reduces staff burdens, enhances provider market position
By
Paul Tanico
Feb 01, 2024
By adopting a comprehensive strategy that balances clinical insights, lifestyle interventions and economic considerations, staff members can unlock the potential for improved outcomes and elevate the facility’s...
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.